SAGE Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 598

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $795M

  • Investors
  • 1

SAGE Therapeutics General Information

Description

Developer of brain health medicines designed to treat central nervous system disorders. The company's technology offers positive allosteric modulators, GABA receptor targeting, NMDA receptor targeting, once-daily oral dosing, rapid-acting antidepressant effects, and intravenous injection formulations, enabling patients to access therapies for postpartum depression, major depressive disorder, and other neuropsychiatric conditions.

Contact Information

Website
www.sagerx.com
Formerly Known As
Sterogen Biopharma
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 55 Cambridge Parkway
  • Cambridge, MA 02142
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 55 Cambridge Parkway
  • Cambridge, MA 02142
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SAGE Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
17. Merger/Acquisition 31-Jul-2025 $795M Completed Generating Revenue
16. Merger/Acquisition 27-Jan-2025 Cancelled Generating Revenue
15. PIPE 19-Oct-2024 Completed Generating Revenue
14. PIPE 31-Dec-2020 Completed Generating Revenue
13. Secondary Transaction - Open Market 31-Mar-2018 Completed Generating Revenue
12. 2PO 20-Sep-2017 Completed Generating Revenue
11. Secondary Transaction - Open Market 31-Mar-2017 Completed Generating Revenue
10. PIPE 08-Sep-2016 Completed Generating Revenue
9. Secondary Transaction - Open Market 31-Mar-2016 $292M Completed Generating Revenue
8. 2PO 14-Apr-2015 $120M $292M Completed Generating Revenue
To view SAGE Therapeutics’s complete valuation and funding history, request access »

SAGE Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of brain health medicines designed to treat central nervous system disorders. The company's technology offers
Drug Discovery
Cambridge, MA
598 As of 2025

Bedminster, NJ
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SAGE Therapeutics Competitors (32)

One of SAGE Therapeutics’s 32 competitors is Intracellular Therapies, a Formerly VC-backed company based in Bedminster, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intracellular Therapies Formerly VC-backed Bedminster, NJ
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
Marinus Pharmaceuticals Private Equity-Backed Radnor, PA
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
Merck & Co. Corporation Rahway, NJ
You’re viewing 5 of 32 competitors. Get the full list »

SAGE Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SAGE Therapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
BB Biotech Asset Manager Minority
Biogen Corporation Minority
EcoR1 Capital Venture Capital Minority
Foresite Capital Growth/Expansion Minority
You’re viewing 5 of 8 investors. Get the full list »

SAGE Therapeutics Investments (1)

SAGE Therapeutics’s most recent deal was a PIPE with Ligand Pharmaceuticals for . The deal was made on 14-May-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ligand Pharmaceuticals 14-May-2014 PIPE Drug Discovery
To view SAGE Therapeutics’s complete investments history, request access »

SAGE Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

27.71 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view SAGE Therapeutics’s complete esg history, request access »

SAGE Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Sage Securities Corporation Cambridge, MA 2019

SAGE Therapeutics FAQs

  • When was SAGE Therapeutics founded?

    SAGE Therapeutics was founded in 2010.

  • Where is SAGE Therapeutics headquartered?

    SAGE Therapeutics is headquartered in Cambridge, MA.

  • What is the size of SAGE Therapeutics?

    SAGE Therapeutics has 598 total employees.

  • What industry is SAGE Therapeutics in?

    SAGE Therapeutics’s primary industry is Drug Discovery.

  • Is SAGE Therapeutics a private or public company?

    SAGE Therapeutics is a Private company.

  • What is the current valuation of SAGE Therapeutics?

    The current valuation of SAGE Therapeutics is .

  • What is SAGE Therapeutics’s current revenue?

    The current revenue for SAGE Therapeutics is .

  • How much funding has SAGE Therapeutics raised over time?

    SAGE Therapeutics has raised $1.15B.

  • Who are SAGE Therapeutics’s investors?

    ARCH Venture Partners, BB Biotech, Biogen, EcoR1 Capital, and Foresite Capital are 5 of 8 investors who have invested in SAGE Therapeutics.

  • Who are SAGE Therapeutics’s competitors?

    Intracellular Therapies, ACADIA Pharmaceuticals, Marinus Pharmaceuticals, Vertex Pharmaceuticals, and Merck & Co. are some of the 32 competitors of SAGE Therapeutics.

  • When was SAGE Therapeutics acquired?

    SAGE Therapeutics was acquired on 31-Jul-2025.

  • Who acquired SAGE Therapeutics?

    SAGE Therapeutics was acquired by Supernus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process